Gyre Therapeutics, Inc. Accounts Receivable, before Allowance for Credit Loss, Current
Gyre Therapeutics, Inc. (GYRE) had Accounts Receivable, before Allowance for Credit Loss, Current of $28.08 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts and Financing Receivable, after Allowance for Credit Loss, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableGrossCurrent · last filed 2026-08-07
- 2026-06-30: Accounts Receivable, before Allowance for Credit Loss, Current $28.08M.
- 2026-03-31: Accounts Receivable, before Allowance for Credit Loss, Current $23.11M.
- 2025-12-31: Accounts Receivable, before Allowance for Credit Loss, Current $31.23M.
- 2025-09-30: Accounts Receivable, before Allowance for Credit Loss, Current $26.06M.
| Period end | Accounts Receivable, before Allowance for Credit Loss, Current | Accounts Receivable, before Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2026-06-30 | $28.08M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $23.11M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $31.23M 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $26.06M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $24.86M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $20.55M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $19.80M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $19.54M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $18.46M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $15.21M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $15.20M 10-K · filed 2025-03-17 | |
| 2022-12-31 | $15.74M 10-K · filed 2024-03-27 | |
| 2021-12-31 | $1.80M 10-K · filed 2022-03-31 | |
| 2020-12-31 | $3.30M 10-K · filed 2021-03-04 | |
| 2019-12-31 | $15.00M 10-K · filed 2020-02-20 | |
| 2017-12-31 | $24.00K 10-K · filed 2018-03-19 | |
| 2017-09-30 | $52.00K 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $135.00K 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $227.00K 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $31.00K 10-K · filed 2018-03-19 | |
| 2016-09-30 | $101.00K 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $462.00K 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $448.00K 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $492.00K 10-K · filed 2017-03-08 | |
| 2015-09-30 | $648.00K 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $87.00K 8-K/A · filed 2015-10-23 | |
| 2014-12-31 | $95.00K 10-K · filed 2016-03-09 | $95.06K 8-K/A · filed 2015-10-23 |
| 2013-12-31 | $96.09K 8-K/A · filed 2015-10-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |